Update History
Condition: Factor V Leiden, Homozygous (also includes compound heterozygous FVL + prothrombin G20210A)
Gene/Gene Panel: F5
Context: Adult
2022/11/21
Released
1.3.3
VTE
(GroupA)
Assessment for VTE risk factors
(GroupA)
IN
Avoid estrogen-containing compounds that exacerbate VTE risk
(GroupA)
9CD
Pharmacological prophylaxis for pregnant women
(GroupA)
8CB
Pharmacological prophylaxis for men and non-pregnant women
(GroupA)
6CD
Assertions
Gene Condition Pairs
Suggested Assertion
Final Assertion
F5
⇔
0008560 THROMBOPHILIA DUE TO ACTIVATED PROTEIN C RESISTANCE; THPH2
Moderate Actionability
Moderate Actionability
2022/03/30
Released
(Under revision)
1.3.2
VTE
(GroupA)
Assessment for VTE risk factors
(GroupA)
IN
Avoid estrogen-containing compounds that exacerbate VTE risk
(GroupA)
9CD
Pharmacological prophylaxis for pregnant women
(GroupA)
8CB
Pharmacological prophylaxis for men and non-pregnant women
(GroupA)
6CD
Internal system migration associated with MONDO name addition.
2022/02/09
Released
1.3.2
VTE
(GroupA)
Assessment for VTE risk factors
(GroupA)
IN
Avoid estrogen-containing compounds that exacerbate VTE risk
(GroupA)
9CD
Pharmacological prophylaxis for pregnant women
(GroupA)
8CB
Pharmacological prophylaxis for men and non-pregnant women
(GroupA)
6CD
Internal system migration associated with MONDO name addition.
2022/02/09
Released
(Under revision)
1.3.1
VTE
(GroupA)
Assessment for VTE risk factors
(GroupA)
IN
Avoid estrogen-containing compounds that exacerbate VTE risk
(GroupA)
9CD
Pharmacological prophylaxis for pregnant women
(GroupA)
8CB
Pharmacological prophylaxis for men and non-pregnant women
(GroupA)
6CD
2020/04/28
Released
1.3.1
VTE
(GroupA)
Assessment for VTE risk factors
(GroupA)
IN
Avoid estrogen-containing compounds that exacerbate VTE risk
(GroupA)
9CD
Pharmacological prophylaxis for pregnant women
(GroupA)
8CB
Pharmacological prophylaxis for men and non-pregnant women
(GroupA)
6CD
2020/04/28
Released
(Under revision)
1.3.0
VTE
(GroupA)
Assessment for VTE risk factors
(GroupA)
IN
Avoid estrogen-containing compounds that exacerbate VTE risk
(GroupA)
9CD
Pharmacological prophylaxis for pregnant women
(GroupA)
8CB
Pharmacological prophylaxis for men and non-pregnant women
(GroupA)
6CD
Internal system migration associated with Gene-Disease scoring groups upgrades.
2019/10/03
Released
1.3.0
VTE
(GroupA)
Assessment for VTE risk factors
(GroupA)
IN
Avoid estrogen-containing compounds that exacerbate VTE risk
(GroupA)
9CD
Pharmacological prophylaxis for pregnant women
(GroupA)
8CB
Pharmacological prophylaxis for men and non-pregnant women
(GroupA)
6CD
Internal system migration associated with Gene-Disease scoring groups upgrades.
2019/04/04
Released
1.2.0
VTE
Assessment for VTE risk factors
IN
Avoid estrogen-containing compounds that exacerbate VTE risk
9CD
Pharmacological prophylaxis for men and non-pregnant women
6CD
Pharmacological prophylaxis for pregnant women
8CB
Internal system migration related to merging adult and pediatric contexts.
2018/11/01
Released
1.1.2
VTE
Assessment for VTE risk factors
IN
Avoid estrogen-containing compounds that exacerbate VTE risk
9CD
Pharmacological prophylaxis for men and non-pregnant women
6CD
Pharmacological prophylaxis for pregnant women
8CB
Internal system migration related to score text replacement from E to N
2018/04/09
Released
1.1.1
VTE
Assessment for VTE risk factors
IN
Avoid estrogen-containing compounds that exacerbate VTE risk
9CD
Pharmacological prophylaxis for men and non-pregnant women
6CD
Pharmacological prophylaxis for pregnant women
8CB
2018/04/09
Released
(Under revision)
1.1.0
VTE
Assessment for VTE risk factors
IN
Avoid estrogen-containing compounds that excerbate VTE risk
9CD
Pharmacological prophylaxis for men and non-pregnant women
6CD
Pharmacological prophylaxis for pregnant women
8CB
2018/03/19
Released
1.1.0
VTE
Assessment for VTE risk factors
IN
Avoid estrogen-containing compounds that excerbate VTE risk
9CD
Pharmacological prophylaxis for men and non-pregnant women
6CD
Pharmacological prophylaxis for pregnant women
8CB
2018/03/19
Released
(Under revision)
1.0.1
VTE
Assessment for VTE risk factors
IN
Avoid estrogen-containing compounds that excerbate VTE risk
10CD
Pharmacological prophylaxis for men and non-pregnant women
7CD
Pharmacological prophylaxis for pregnant women
9CB
2018/01/11
Released
1.0.1
VTE
Assessment for VTE risk factors
IN
Avoid estrogen-containing compounds that excerbate VTE risk
10CD
Pharmacological prophylaxis for men and non-pregnant women
7CD
Pharmacological prophylaxis for pregnant women
9CB
2017/10/23
Released
1.0.0
VTE
Assessment for VTE risk factors
IN
Avoid estrogen-containing compounds that excerbate VTE risk
10CD
Pharmacological prophylaxis for men and non-pregnant women
7CD
Pharmacological prophylaxis for pregnant women
9CB